JP2000505445A5 - - Google Patents

Download PDF

Info

Publication number
JP2000505445A5
JP2000505445A5 JP1997529359A JP52935997A JP2000505445A5 JP 2000505445 A5 JP2000505445 A5 JP 2000505445A5 JP 1997529359 A JP1997529359 A JP 1997529359A JP 52935997 A JP52935997 A JP 52935997A JP 2000505445 A5 JP2000505445 A5 JP 2000505445A5
Authority
JP
Japan
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
JP1997529359A
Other languages
English (en)
Japanese (ja)
Other versions
JP2000505445A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US1997/001422 external-priority patent/WO1997029775A1/en
Publication of JP2000505445A publication Critical patent/JP2000505445A/ja
Publication of JP2000505445A5 publication Critical patent/JP2000505445A5/ja
Ceased legal-status Critical Current

Links

JP9529359A 1996-02-13 1997-02-11 シクロオキシゲナーゼ―２インヒビターとロイコトリエンｂ▲下４▼受容体アンタゴニストの投与の免疫抑制作用 Ceased JP2000505445A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US60058096A 1996-02-13 1996-02-13
US08/600,580 1996-02-13
PCT/US1997/001422 WO1997029775A1 (en) 1996-02-13 1997-02-11 Compositions comprising a cyclooxygenase-2 inhibitor and a leukotriene b4 receptor antagonist

Publications (2)

Publication Number Publication Date
JP2000505445A JP2000505445A (ja) 2000-05-09
JP2000505445A5 true JP2000505445A5 (enExample) 2004-11-18

Family

ID=24404169

Family Applications (1)

Application Number Title Priority Date Filing Date
JP9529359A Ceased JP2000505445A (ja) 1996-02-13 1997-02-11 シクロオキシゲナーゼ―２インヒビターとロイコトリエンｂ▲下４▼受容体アンタゴニストの投与の免疫抑制作用

Country Status (10)

Country Link
US (3) US6172096B1 (enExample)
EP (2) EP0880362B1 (enExample)
JP (1) JP2000505445A (enExample)
AT (1) ATE296114T1 (enExample)
AU (1) AU2250097A (enExample)
CA (1) CA2246356A1 (enExample)
DE (1) DE69733338T2 (enExample)
ES (1) ES2243978T3 (enExample)
PT (1) PT880362E (enExample)
WO (1) WO1997029775A1 (enExample)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6512121B2 (en) 1998-09-14 2003-01-28 G.D. Searle & Co. Heterocyclo substituted hydroxamic acid derivatives as cyclooxygenase-2 and 5-lipoxygenase inhibitors
CA2223154A1 (en) 1995-06-02 1996-12-05 G.D. Searle & Co. Heterocyclo substituted hydroxamic acid derivatives as cyclooxygenase-2 and 5-lipoxygenase inhibitors
CA2246336A1 (en) * 1996-02-13 1997-08-21 G.D. Searle & Co. Combinations, having immunosuppressive effects, containing a cyclooxygenase-2 inhibitor and a leukotriene a4 hydrolase inhibitor
JP2000504723A (ja) 1996-02-13 2000-04-18 ジー．ディー．サール アンド カンパニー シクロオキシゲナーゼ―２阻害剤および５―リポキシゲナーゼ阻害剤投与の免疫抑制効果
ATE296114T1 (de) * 1996-02-13 2005-06-15 Searle & Co Zubereitungen, enthaltend einen cyclooxygenase-2- inhibitor und einen leukotrien-b4-rezeptor- antagonisten
CA2313049A1 (en) * 1997-12-17 1999-06-24 Cornell Research Foundation, Inc. Cyclooxygenase-2 inhibition
US7041694B1 (en) * 1997-12-17 2006-05-09 Cornell Research Foundation, Inc. Cyclooxygenase-2 inhibition
US6767890B1 (en) * 1998-11-18 2004-07-27 Coastside Bio Resources Peptides having anti-cancer and anti-inflammatory activity
EP1282423A2 (en) * 2000-05-11 2003-02-12 Oklahoma Medical Research Foundation Prevention of insulin-dependent diabetes, complications thereof, or allograft rejection by inhibition of cyclooxygenase-2 activity with ns398 or pdtc
GB0112348D0 (en) * 2001-05-19 2001-07-11 Smithkline Beecham Plc Compounds
AR038957A1 (es) 2001-08-15 2005-02-02 Pharmacia Corp Terapia de combinacion para el tratamiento del cancer
CA2484989A1 (en) * 2002-05-02 2003-11-27 The Washington University Methods and compositions for treating t cell mediated inflammatory/autoimmune diseases and disorders in subjects having a glucocorticoid regulation deficiency
US7507531B2 (en) 2002-10-17 2009-03-24 Decode Genetics Chf. Use of 5-lipoxygenase activating protein (FLAP) gene to assess susceptibility for myocardial infarction
US7851486B2 (en) 2002-10-17 2010-12-14 Decode Genetics Ehf. Susceptibility gene for myocardial infarction, stroke, and PAOD; methods of treatment
US7354574B2 (en) * 2002-11-07 2008-04-08 Advanced Ocular Systems Limited Treatment of ocular disease
RS20050390A (sr) * 2002-11-26 2008-04-04 Boehringer Ingelheim Pharma Gmbh. & Co.Kg., Farmaceutska kompozicija koja obuhvata ltb4 antagonist i koks-2 inhibitor ili kombinovani koks1/2 inhibitor
US20040242676A1 (en) * 2003-05-30 2004-12-02 Alessi Thomas R. Method of mitigating the adverse effects of IL-2
US7083802B2 (en) * 2003-07-31 2006-08-01 Advanced Ocular Systems Limited Treatment of ocular disease
CN102144961A (zh) 2003-09-18 2011-08-10 参天制药株式会社 经巩膜递送
US7087237B2 (en) * 2003-09-19 2006-08-08 Advanced Ocular Systems Limited Ocular solutions
US20050181018A1 (en) * 2003-09-19 2005-08-18 Peyman Gholam A. Ocular drug delivery
US7083803B2 (en) * 2003-09-19 2006-08-01 Advanced Ocular Systems Limited Ocular solutions
WO2005102388A1 (ja) * 2004-04-26 2005-11-03 Ono Pharmaceutical Co., Ltd. 新規なｂｌｔ２介在性疾患、ｂｌｔ２結合剤および化合物
WO2006030753A1 (ja) * 2004-09-13 2006-03-23 Santen Pharmaceutical Co., Ltd. 角結膜障害治療剤
US8663639B2 (en) 2005-02-09 2014-03-04 Santen Pharmaceutical Co., Ltd. Formulations for treating ocular diseases and conditions
EP1853259A1 (en) 2005-02-09 2007-11-14 Macusight, Inc. Formulations for ocular treatment
WO2006113261A2 (en) * 2005-04-14 2006-10-26 Bristol-Myers Squibb Company Inhibitors of 11-beta hydroxysteroid dehydrogenase type i
AU2006270041B2 (en) 2005-07-18 2011-08-18 Minu, Llc Enhanced ocular neuroprotection/neurostimulation
US20070014760A1 (en) * 2005-07-18 2007-01-18 Peyman Gholam A Enhanced recovery following ocular surgery
EP2001438A2 (en) 2006-02-09 2008-12-17 Macusight, Inc. Stable formulations, and methods of their preparation and use
EP2001466B1 (en) 2006-03-23 2016-01-06 Santen Pharmaceutical Co., Ltd Low-dose rapamycin for the treatment of vascular permeability-related diseases
US20090291883A1 (en) * 2006-07-14 2009-11-26 Boston Medical Center Corporation Combination of an immunosuppressive agent and nonsteroidal anti -inflammatory drugs to treat disease
US20090017140A1 (en) * 2007-07-09 2009-01-15 Peter Koepke Maytenus abenfolia extract and methods of extracting and using such extract
US20090035395A1 (en) * 2007-08-01 2009-02-05 Peter Koepke Spondias mombin l. extract and methods of extracting and using such extract
US7879369B2 (en) * 2007-09-18 2011-02-01 Selvamedica, Llc Combretum laurifolium Mart. extract and methods of extracting and using such extract
US10058542B1 (en) 2014-09-12 2018-08-28 Thioredoxin Systems Ab Composition comprising selenazol or thiazolone derivatives and silver and method of treatment therewith

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS59196839A (ja) 1983-04-21 1984-11-08 Sankyo Co Ltd フエニル酢酸誘導体
US4923891A (en) 1987-09-24 1990-05-08 G. D. Searle & Co. Leukotriene LTD4 and LTB4 antagonists
US4970234A (en) 1987-12-08 1990-11-13 G. D. Searle & Co. Furyl, phenylene, and thienyl leukotriene B4 analogues
US4889935A (en) 1987-12-18 1989-12-26 American Home Products Corporation Aminoguanidine derivatives
US4871771A (en) 1988-02-04 1989-10-03 Smithkline Beckman Corporation Leukotriene antagonists
US5384318A (en) * 1989-06-22 1995-01-24 Pfizer Inc. Substituted sulfonamides and related compounds in the treatment of asthma, arthritis and related diseases
US5256686A (en) 1989-06-27 1993-10-26 Ono Pharmaceutical Co., Ltd. Phenylalkan(en)oic acid
US5212198A (en) 1990-05-10 1993-05-18 G. D. Searle & Co. Alkoxy-substituted dihydrobenzopyran-2-carboxylic acids and derivatives thereof
US5121198A (en) * 1990-06-28 1992-06-09 Eastman Kodak Company Method of setting the contrast of a color video picture in a computer controlled photographic film analyzing system
US5124350A (en) 1990-06-28 1992-06-23 G. D. Searle & Co. Leukotriene b4 antagonists
FR2665159B1 (fr) 1990-07-24 1992-11-13 Rhone Poulenc Sante Nouveaux derives de la pyridine et de la quinoleine, leur preparation et les compositions pharmaceutiques qui les contiennent.
JPH0439864U (enExample) * 1990-07-30 1992-04-03
US5232948A (en) 1990-09-10 1993-08-03 Rhone-Poulenc Rorer Pharmaceuticals Inc. Substituted monocyclic aryl compounds exhibiting selective leukotriene b4 antagonist activity
US5210208A (en) 1990-09-24 1993-05-11 Rhone-Poulenc Rorer Pharmaceuticals Inc. Disubstituted aryl compounds exhibiting selective leukotriene b4 antagonist activity
IE913655A1 (en) 1990-11-06 1992-05-22 Zeneca Ltd Synergistic agents
US5246965A (en) * 1991-06-11 1993-09-21 Ciba-Geigy Arylethers, their manufacture and methods of treatment
US5272178A (en) 1991-11-18 1993-12-21 G. D. Searle & Co. Compounds of cyclic phenolic thioethers which are useful in stimulating and inhibiting superoxide generation
DE4141746A1 (de) * 1991-12-13 1993-06-17 Schering Ag 20-methyl-substituierte vitamin d-derivate
GB9215921D0 (en) 1992-07-27 1992-09-09 Wellcome Found Anti-inflammatory compounds
DE4228201A1 (de) * 1992-08-25 1994-03-03 Schering Ag Neue Leukotrien-B¶4¶-Antagonisten, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
US5604260A (en) 1992-12-11 1997-02-18 Merck Frosst Canada Inc. 5-methanesulfonamido-1-indanones as an inhibitor of cyclooxygenase-2
DE9422447U1 (de) 1993-01-15 2002-10-17 G.D. Searle LLC, Chicago, Ill. 3,4-Diarylthiophene und Analoga davon, sowie deren Verwendung als entzündungshemmende Mittel
US5409944A (en) 1993-03-12 1995-04-25 Merck Frosst Canada, Inc. Alkanesulfonamido-1-indanone derivatives as inhibitors of cyclooxygenase
US5380740A (en) 1993-04-28 1995-01-10 G. D. Searle & Co. Anti-inflammatory compounds, compositions and method of use thereof
AU6718494A (en) 1993-05-13 1994-12-12 Merck Frosst Canada Inc. 2-substituted-3,4-diarylthiophene derivatives as inhibitors of cyclooxygenase
US5380738A (en) 1993-05-21 1995-01-10 Monsanto Company 2-substituted oxazoles further substituted by 4-fluorophenyl and 4-methylsulfonylphenyl as antiinflammatory agents
US5474995A (en) 1993-06-24 1995-12-12 Merck Frosst Canada, Inc. Phenyl heterocycles as cox-2 inhibitors
US5412151A (en) 1993-10-22 1995-05-02 Eastman Chemical Company Thermosetting coating compositions
US5344991A (en) 1993-10-29 1994-09-06 G.D. Searle & Co. 1,2 diarylcyclopentenyl compounds for the treatment of inflammation
US5466823A (en) * 1993-11-30 1995-11-14 G.D. Searle & Co. Substituted pyrazolyl benzenesulfonamides
US5434178A (en) 1993-11-30 1995-07-18 G.D. Searle & Co. 1,3,5 trisubstituted pyrazole compounds for treatment of inflammation
KR100263817B1 (ko) * 1993-11-30 2000-08-16 윌리암스 로저 에이 염증치료용 치환 피라졸일벤젠술폰아미드
KR100297091B1 (ko) 1993-12-09 2001-11-05 고래마츠 교지 크롬-프리벽돌
US5393790A (en) 1994-02-10 1995-02-28 G.D. Searle & Co. Substituted spiro compounds for the treatment of inflammation
US5486534A (en) * 1994-07-21 1996-01-23 G. D. Searle & Co. 3,4-substituted pyrazoles for the treatment of inflammation
US5620999A (en) * 1994-07-28 1997-04-15 Weier; Richard M. Benzenesulfonamide subtituted imidazolyl compounds for the treatment of inflammation
US5616601A (en) * 1994-07-28 1997-04-01 Gd Searle & Co 1,2-aryl and heteroaryl substituted imidazolyl compounds for the treatment of inflammation
US5521213A (en) 1994-08-29 1996-05-28 Merck Frosst Canada, Inc. Diaryl bicyclic heterocycles as inhibitors of cyclooxygenase-2
US5686470A (en) * 1995-02-10 1997-11-11 Weier; Richard M. 2, 3-substituted pyridines for the treatment of inflammation
US5633272A (en) * 1995-02-13 1997-05-27 Talley; John J. Substituted isoxazoles for the treatment of inflammation
JPH11507669A (ja) * 1995-06-12 1999-07-06 ジー．ディー．サール アンド カンパニー シクロオキシゲナーゼ−２インヒビターとロイコトリエンｂ▲下４▼受容体アンタゴニストの組合せによる炎症と炎症関連疾患の治療
US5700816A (en) * 1995-06-12 1997-12-23 Isakson; Peter C. Treatment of inflammation and inflammation-related disorders with a combination of a cyclooxygenase-2 inhibitor and a leukotriene A4 hydrolase inhibitor
US6096728A (en) * 1996-02-09 2000-08-01 Amgen Inc. Composition and method for treating inflammatory diseases
ATE296114T1 (de) * 1996-02-13 2005-06-15 Searle & Co Zubereitungen, enthaltend einen cyclooxygenase-2- inhibitor und einen leukotrien-b4-rezeptor- antagonisten

Similar Documents

Publication Publication Date Title
JP2000502280A5 (enExample)
JP2000501771A5 (enExample)
JP2000501599A5 (enExample)
JP2000501018A5 (enExample)
JP2000500076A5 (enExample)
JP2000511019A5 (enExample)
JP2000501324A5 (enExample)
JP2000502472A5 (enExample)
JP2000501825A5 (enExample)
JP2000501338A5 (enExample)
JP2000500874A5 (enExample)
JP2000502425A5 (enExample)
JP2000502485A5 (enExample)
JP2000502568A5 (enExample)
JP2000501774A5 (enExample)
JP2000500912A5 (enExample)
JP2000508289A5 (enExample)
JP2000502570A5 (enExample)
JP2000501876A5 (enExample)
JP2000501744A5 (enExample)
JP2000501229A5 (enExample)
JP2000502316A5 (enExample)
JP2000500857A5 (enExample)
JP2000502714A5 (enExample)
JP2000501569A5 (enExample)